Constantine S Tam, Stephen Opat, Shirley P D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramon Garcia-Sanz, Helen McCarthy, Stephen P Mulligan, Alessandra Tedeschi, Jorge J Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward N Libby, Jeffrey V Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C Minnema, Christian Buske, Véronique Leblond, Steven P Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai Y Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios-Athanasios A Dimopoulos
The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKi), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on pretreatment bone marrow samples from 98 zanubrutinib-treated and 92 ibrutinib-treated patients with mutated (MUT) MYD88 and 20 zanubrutinib-treated patients with wild-type (WT) MYD88. Of 329 mutations in 52 genes, mutations in CXCR4 (25.7%), TP53 (24.8%), ARID1A (15...
February 5, 2024: Blood Advances